DAVID ANAKWENZE: Open Payments
NPI 1356306559 · FLORENCE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,689 in 66 payments from 12 companies in 2025. Trend: 2023 $1,308 · 2024 $1,848 · 2025 $1,689
Food & beverage: $1,579Education: $109
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 22 | $555 |
| Vanda Pharmaceuticals Inc. | 8 | $219 |
| Teva Pharmaceuticals USA, Inc. | 5 | $209 |
| Neurocrine BioSciences, Inc. | 8 | $182 |
| Otsuka America Pharmaceutical, Inc. | 3 | $150 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $146 |
| E.R. Squibb & Sons, L.L.C. | 4 | $89 |
| Almatica Pharma LLC | 2 | $45 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Janssen Pharmaceuticals, Inc | 2 | $31 |
Products named: ARISTADA, FANAPT, INGREZZA, CAPLYTA, LYBALVI, REXULTI, COBENFY, AUSTEDO XR.
Industry payments across AL — which companies pay providers there.
